EcoDrugPlus

Glutamate Receptor 1

Ensembl ID : ENSXMAG00000010477
Gene Symbol: LOC102221441
3 Cross references
250 Possible Orthologues:

Glutamate Receptor 1-Like

Ensembl ID : ENSXMAG00000014975
Gene Symbol: LOC102232915
3 Cross references
249 Possible Orthologues:

Glutamate Receptor 4

Ensembl ID : ENSXMAG00000008529
Gene Symbol: LOC102224370
3 Cross references
249 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 1

Ensembl ID : ENSXMAG00000003092
Gene Symbol: LOC102220646
3 Cross references
205 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2a-Like

Ensembl ID : ENSXMAG00000000907
Gene Symbol: LOC102226347
2 Cross references
98 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2d-Like

Ensembl ID : ENSXMAG00000014145
Gene Symbol: LOC102220283
2 Cross references
214 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2d-Like

Ensembl ID : ENSXMAG00000012023
Gene Symbol: LOC102219807
2 Cross references
212 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 3b-Like

Ensembl ID : ENSXMAG00000024090
Gene Symbol: LOC102223545
2 Cross references
226 Possible Orthologues:

Glutamate Receptor Ionotropic, Kainate 1-Like

Ensembl ID : ENSXMAG00000017630
Gene Symbol: LOC102238325
2 Cross references
245 Possible Orthologues:

Glutaminase Kidney Isoform, Mitochondrial-Like

Ensembl ID : ENSXMAG00000005850
Gene Symbol: LOC102223675
2 Cross references
232 Possible Orthologues:

Glutaminase Kidney Isoform, Mitochondrial-Like

Ensembl ID : ENSXMAG00000010380
Gene Symbol: LOC102225213
3 Cross references
230 Possible Orthologues:

Glycogen Synthase Kinase 3 Alpha

Ensembl ID : ENSXMAG00000010809
Gene Symbol: GSK3A
3 Cross references
186 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).